Hosted on MSN12mon
Landmark FDA Approval of Rezdiffra Marks New Era for NASH TreatmentThis game-changing medication, used in conjunction with diet and exercise, targets noncirrhotic NASH—a serious liver condition—associated with moderate to advanced liver fibrosis. For over 15 ...
Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has become the first drug to be approved by the US Food and Drug Administration (FDA) as a treatment for noncirrhotic nonalcoholic ...
Researchers at Georgetown University have developed a new drug called CTPI-2, which targets a key gene known as Slc25a1. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results